Regeneron Pharmaceuticals, Inc.
17.beta.-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

Abstract:

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.